Comparative Pharmacology
Head-to-head clinical analysis: LAMICTAL versus LYRICA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LAMICTAL versus LYRICA.
LAMICTAL vs LYRICA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lamotrigine is a triazine antiepileptic drug that inhibits voltage-sensitive sodium channels, stabilizing neuronal membranes and modulating presynaptic transmitter release of excitatory amino acids like glutamate and aspartate.
Binds to the α2-δ subunit of voltage-gated calcium channels, reducing calcium influx and inhibiting release of excitatory neurotransmitters including glutamate, norepinephrine, and substance P.
Initial: 25 mg orally once daily for 2 weeks, then 50 mg once daily for 2 weeks, then 100 mg once daily for 1 week, then 150 mg twice daily or 200 mg twice daily (if taking valproate, reduced regimen).
Oral: 75-150 mg twice daily or 50-100 mg three times daily; maximum 600 mg/day. Start at 75 mg twice daily.
None Documented
None Documented
14 hours (monotherapy); 7 hours (with enzyme-inducers); 30 hours (with valproate).
Terminal elimination half-life is 6.3 hours (range 5.5–6.7 hours) in patients with normal renal function. Half-life increases in renal impairment (up to 48 hours in anuria).
Renal (70% as glucuronide metabolites, 2% as unchanged drug); fecal (2%); biliary (minor).
Renal excretion of unchanged drug accounts for approximately 90% of elimination; less than 1% is secreted in feces or bile. Dose adjustment required in renal impairment (CrCl <60 mL/min).
Category C
Category C
Anticonvulsant
Anticonvulsant